OPKO Health (OPK) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
18 Jun, 2026Opening remarks and agenda
Meeting opened by the Chairman and CEO, with board members and executive team introduced, including key leaders from various divisions.
Secretary and inspector of elections appointed; business portion to be followed by company update and Q&A.
Cautionary statements made regarding forward-looking statements and associated risks.
Confirmation of meeting requirements, record date, and distribution of meeting materials.
Board and executive committee updates
Board members with diverse backgrounds in business and science acknowledged for their contributions.
Shareholder proposals
Four proposals presented: election of directors, approval of 2026 equity incentive plan, advisory vote on executive compensation, and ratification of Ernst & Young as auditor.
All proposals approved by requisite stockholder vote; directors elected until 2027 annual meeting.
Latest events from OPKO Health
- Q2 2026 revenue rose, losses narrowed, and cash reserves strengthened amid pipeline and partnership gains.OPK
Q2 2026 - Multiple clinical milestones expected in 2024-2025, including key data from MDX-2001 and Merck EBV vaccine.OPK
Jefferies Global Healthcare Conference 2026 - Approval of the 2026 Equity Incentive Plan is sought to maintain equity-based compensation.OPK
Proxy filing - Advancing a broad clinical pipeline and global partnerships, supported by strong financials.OPK
Corporate presentation - Proxy seeks approval for director elections, new equity plan, executive pay, and auditor ratification.OPK
Proxy filing - Key votes include board elections, equity plan approval, say-on-pay, and auditor ratification.OPK
Proxy filing - Q4 revenue dropped post-divestiture, but R&D and pharma growth support a strong 2026 outlook.OPK
Q4 2025 - Q3 2025 saw a major asset sale, higher operating income, and strong cash reserves.OPK
Q3 2025 - Q1 2025 saw lower losses, strong cash, asset sales, and a $225M oncology deal with LabCorp.OPK
Q1 2025